TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has begun production on novel cannabis metered dose inhalers for the EU and the United Kingdom, made to global pharmaceutical standards and distributed by Blackpoint Limited (“Blackpoint”), MediPharm’s exclusive sales and distribution partner in those territories. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Canopy Growth Corporation securities during the specified class period of the upcoming lead plaintiff deadline on June 3, 2025 [1] Group 1: Class Action Details - Investors who purchased Canopy Growth securities between May 30, 2024, and February 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lawsuit alleges that Canopy Growth made false and misleading statements regarding its financial health and cost management, which negatively impacted investors when the truth was revealed [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing clients [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Canopy Growth Corporation securities between May 30, 2024, and February 6, 2025, of the June 3, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Canopy Growth securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Canopy Growth made false and misleading statements regarding the costs associated with the launch of its Claybourne product and the impact on its gross margins [5]. - It is claimed that the company overstated the effectiveness of its cost reduction measures while downplaying financial issues, leading to investor damages when the true information became public [5].

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Canopy Growth Corporation ("Canopy Growth Corporation" or the "Company") (NASDAQ: CGC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Canopy Growth Corporation investors who were adversely affected by alleged securities fraud between May 30, 2024 and February 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zl ...

Core Viewpoint - MediPharm Labs Corp. has successfully removed all conditions precedent related to the sale of its Hope Facility to Rubicon Organics Inc. for $4.5 million, which is expected to close in June 2025, enhancing the company's cash position and maintaining its virtually debt-free status [1][2][3]. Financial Impact - The $4.5 million proceeds from the sale will support MediPharm's strategy to deliver long-term value for shareholders and partners, focusing on international growth and acquisition opportunities [3]. - Since the implementation of its cost-reduction strategy in Q2 2022, MediPharm has reduced operating and overhead costs by approximately $42 million annually [4]. Asset Management - The Hope Facility was acquired during the VIVO Cannabis Inc. acquisition in 2023, and all commercial activities at this facility ceased in 2024, consolidating operations at other facilities to reduce costs [3]. - The total value of asset sales since 2022, including the Hope Facility, amounts to approximately $14 million, contributing to cost reduction and strengthening the balance sheet [3]. Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and products, operating under Good Manufacturing Practices [5]. - The company holds a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale GMP license for extracting multiple natural cannabinoids [6]. - The acquisition of VIVO Cannabis Inc. in 2023 expanded MediPharm's reach to medical patients in Canada, Australia, and Germany [7].

Core Insights - Rubicon Organics Inc. has successfully removed all conditions precedent related to its purchase and sale agreement for the Hope Facility, a 47,500 square foot indoor cultivation facility in British Columbia [1][2][3] - The acquisition is expected to significantly enhance the company's premium production capacity and support its growth strategy, with the first harvest anticipated by the end of 2025 and revenue expected in early 2026 [2][4] Company Overview - Rubicon Organics is a licensed producer focused on cultivating and selling organic certified and premium cannabis products, with a vertically integrated structure through its subsidiary Rubicon Holdings Corp [6][7] - The company aims to achieve industry-leading profitability through its premium cannabis flower, product innovation, and brand portfolio management, which includes flagship brands such as Simply Bare™ Organic, 1964 Supply Co™, Wildflower™, and Homestead Cannabis Supply™ [6][7] Facility Details - The Hope Facility is designed with advanced cultivation technology and is expected to have an annual production capacity of up to 4,500 kilograms [4] - The facility will play a crucial role in expanding Rubicon Organics' premium product offerings to meet rising demand in the market [4][6]

Core Insights - Tilray Medical has launched its cannabis brand Good Supply in Germany, aiming to provide affordable and reliable medical cannabis options for patients [1][2][3] - The introduction of Good Supply reflects Tilray's commitment to enhancing patient care and empowering healthcare professionals with innovative medical cannabis solutions [2][3] - Good Supply offers a variety of cannabis strains, available in both 15g and 500g, catering to the diverse needs of patients [2][7] Company Overview - Tilray Medical is a leading player in the global medical cannabis industry, with operations in Canada, Portugal, and Germany, and is recognized for its commitment to quality and innovation [3][4] - The company has established itself as a trusted supplier of medical cannabis, with a portfolio that includes multiple brands designed to meet patient needs worldwide [4][6] - Tilray Brands, Inc. operates as a global lifestyle and consumer packaged goods company, focusing on cannabis, wellness, and entertainment, with a mission to inspire joy and create memorable experiences [6]

Group 1 - The Cronos Group is recognized as a pioneer in the cannabis industry, known for its strong brands and strategic investment partnerships [1] - The company is experiencing continuous revenue growth and has established itself as a significant player in the market [1] - The investment approach focuses on identifying undervalued businesses with strong fundamentals, aiming to build and preserve generational wealth [1] Group 2 - The investment strategy involves screening approximately 10,000 publicly listed companies to find dominant players in resilient sectors [1] - The emphasis is on companies led by shareholder-aligned management teams that generate strong free cash flows [1]

Core Viewpoint - MediPharm Labs Corp. is addressing concerns regarding Regan McGee, a dissident shareholder and CEO of Apollo Technology Capital Corporation, who is seeking to elect himself and five other directors to the MediPharm board at the upcoming shareholder meeting [1][2]. Group 1: Allegations Against Regan McGee - Allegations have been made against Mr. McGee regarding his business conduct, including claims of misusing company resources and setting his own compensation through a conflicted process [3][6]. - Former colleagues of Mr. McGee have accused him of misrepresenting the nature of Nobul Technologies Inc.'s business, claiming it was a technology innovator when it primarily operated as a traditional real estate brokerage [7][8]. - There are serious allegations that Mr. McGee and his associates misled investors about Nobul's financial health and used funds for personal enrichment rather than business expansion [12][14]. Group 2: Legal Proceedings - Multiple litigation cases involving Nobul Technologies Inc. and Mr. McGee have been cited, including claims of fraudulent misrepresentation and breach of fiduciary duty [26][30]. - The allegations in these cases include claims that Mr. McGee used Nobul as a façade to deceive investors, leading to significant financial losses for those who invested based on misleading information [13][14]. - The legal actions also highlight governance issues, with former directors expressing concerns about Mr. McGee's control over the company and the lack of transparency in operations [10][11]. Group 3: MediPharm's Position - MediPharm urges shareholders to support its nominees and resolutions by voting with the GREEN proxy, emphasizing the importance of governance and the qualifications of its board members [16][17]. - The company has communicated that shareholders should disregard any outreach from the dissident group and focus on the information provided by MediPharm [18].

Strategic transaction will deepen Blüm's indirect stake in Cookies and will further align its platform with one of the most recognized cannabis brands in the U.S.DOWNEY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded holding company and cannabis operator, today announced the execution of a binding term sheet to acquire 100% of the membership interest in a holding company (the “Target”). The ...